If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
A galcanezumab pregnancy registry is currently under review with the United States Food and Drug Administration.
Pregnancy or related events can be reported to
the Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov/medwatch, or
Enclosed Prescribing Information
Date of Last Review: May 09, 2019